Linked Life Data

20135894

Source:http://linkedlifedata.com/resource/pubmed/id/20135894

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-2-8
pubmed:abstractText
We currently rely on large randomized controlled trials and meta-analyses to make clinical decisions; this places us at a risk of discarding subgroup or individually specific treatment options owing to their failure to prove efficacious across entire populations. There is a new era emerging in personalized medicine that will focus on individual differences that are not evident phenomenologically. Much research is directed towards identifying genes, endophenotypes, and biomarkers of disease that will facilitate diagnosis and predict treatment outcome. We are at the threshold of being able to predict treatment response, primarily through genetics and neuroimaging. In this review we discuss the most promising markers of treatment response and adverse effects emerging from the areas of pharmacogenetics and neuroimaging in depression and schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1294-8322
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
363-76
pubmed:dateRevised
2011-10-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine.
pubmed:affiliation
Centre for Addiction and Mental Health, University of Toronto, Canada.
pubmed:publicationType
Journal Article, Review